Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Triple Negative Breast Cancer Clinical Trial

Official title:

Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in Combination With Cyclophosphamide as Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03799679
• Other study ID #: 1808189-7
• Status: Recruiting
• Phase: Phase 4
• Start date: November 26, 2018
• Est. completion date: February 1, 2020

Study information

• Verified date: January 2019
• Source: Fudan University
• Contact: Zhimin Shao
• Phone: 18017312288
• Email: szm[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single arm, two-stage Simon Design study for women with Triple Negative Breast Cancer treated with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin.

The primary objective of the trial is to evaluate of the efficacy and safety of weekly Nanoparticle Albumin-Bound Paclitaxel(Nab-P) Followed by Dose-Intensive Epirubicin in Combination with Cyclophosphamide as Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.

The primary endpoint of the study is to to assess Pathological complete response rate（pCR）using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)..

The total number of patients to be included in this study is 60 patients.

The duration of the study, from first patient visit to last patient visit will be approximately 19 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 1, 2020
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age: from 18 to 70 years old, female.

2. Has histologically or cytologically confirmed unilateral primary invasive breast cancer with a clinical stage of T2-4NanyM0.

3. The expression of ER, PR, HER-2 was negative by immunohistochemistry (IHC), if HER2 expression is 2+ patients need to be confirmed by in situ hybridization to detect no HER-2 gene amplification.

4. At least one measurable objective lesion according to RECIST 1.1 criteria.

5. ECOG performance status of 0-1.

6. LVEF=55%.

7. Bone marrow function: Neutrophils = 1.5×109/L, platelets = 100×109/L, and hemoglobin = 90 g/L.

8. Liver and renal function: Serum creatinine = 1.5 times the upper limit of normal. AST and ALT = 2.5 times the upper limit of normal Total bilirubin = 1.5 times the upper limit of normal, or = 2.5 times the upper limit of normal in patients with Gilbert's syndrome.

9. Has good compliance with the planned treatment, understand the study process and sign written informed consent.

Exclusion Criteria:

1. Any prior cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiation therapy.

2. Patients with grade II or higher heart disease scored by the New York Heart Association (NYHA).

3. Severe systemic infection, or with other serious diseases.

4. Patients with known hypersensitivity or intolerance to chemotherapeutic agents or their excipients.

5. Other malignancies have occurred in the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin carcinoma.

6. Pregnant or lactating, and who refuse to take appropriate contraception during the course of this trial.

7. Have participated in other study studies within 30 days prior to the first dose of study drug.

8. Patients who, in the opinion of the Investigator, are not suitable for participation in the study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Chemotherapeutic Agent
Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide. Drug: Epirubicin 90 mg/m² given IV Drug: Cyclophosphamide 600 mg/m² given IV

Locations

Country	Name	City	State
China	Cancer Hospital/ Institute, Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is pathological complete remission (pCR)	Histopathological examination of breast and axillary lymph node specimens without invasive cancer cell remnants. Complete pathological response is also considered to be achieved if only in situ cancer cell remnants are present in the surgical specimens.	2 months
Secondary	The second endpoint includes the objective response rate (ORR)	The second endpoint ORR composed of tumor response classifications of complete response (CR) and partial response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases.	2 months
Secondary	Breast conserving surgery(BCS) rate	Percentage of patients undergoing breast-conserving surgery after neoadjuvant therapy as a whole evaluable.	2 months
Secondary	Adverse events (AE)	Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. Patients were assessed for toxicities before each administration, and toxicity was graded accordingly.	2 months